Owner Scorecard


← All companies ← OCGN Manual ODC → ← NVS Pharmaceuticals OGI →

OCUL, Ocular Therapeutix Inc.

Pharmaceuticals consumer brand UnprofitableDistress / turnaroundNet current asset value

A pharmaceutical business, where patents grant a temporary monopoly the pipeline must keep refilling.

Latest annual: FY2025 10-K
OCUL · Ocular Therapeutix Inc.
I

The business

What it sells, where the money comes from, the kind of company it is.

Revenue · FY2025
$52M
−18.5% YoY · 24% 5-yr CAGR
Vital signs · TTM
Cash & investments $599M
Cash burn · annual $238M
Runway 2.5 yrs

Next report Est. 11/2–11/6 · the 10-Q for the quarter ended late September · due within 40 days of period end · has filed ~35 days after · the wire records it on arrival

The business in brief

read the 10-K →

What this business is and what moves its needle, from its own SEC filings.

Situation
Unprofitable. No sustained operating profit across the record; an earnings multiple has nothing to rest on. What the record does show is revenue, the gross-margin trajectory, and the burn against the cash on hand. Distress / turnaround. Thin interest coverage, or operating cash burned against real debt, across the record. The balance sheet carries this situation; the debt schedule sets the clock. Net current asset value. Current assets alone exceed every liability combined, and the surplus is most of the balance sheet: the shape Graham called a net-net.
What moves the needle
Operating margin has run around −224% through the cycle on a 88% gross margin, the operating line in the red even at its best — so the lever is whether the spending below the gross line can come down enough to clear a profit: revenue growth against the cost curve, and the cash runway until it does. Stock-based pay runs about 52% of sales, a real and recurring claim on owners that the GAAP margin understates. Read this kind of business on the pipeline against the patent cliff, and pricing. On its own account, the filing leans hardest on pricing power & competition, set against the numbers in what the filing emphasizes, below.
Is it a good business?
Return on capital has rarely cleared the cost of capital (median −708%, above 15% in 0 of 3 years). Owner earnings, the cash-based check, have been thin too. This is price-taker territory, where the balance sheet and the cycle matter more than any multiple; the rest is in the 10-K.

Every line is arithmetic on the company's filings, shown in full in the sections below.

II

The record

Ten years of arithmetic, read across the cycle.

The record, 2016–2025

realized figures from each filing · older years to the left
2016’162017’172018’182019’192020’202021’212022’222023’232024’242025’25TTMTTMJun 2026
Income statement
$2M$2M$2M$4M$17M$44M$51M$58M$64M$52M$52MRevenueRevenue
$1M$1M$2M$2MGross profitGross prof.
77%76%77%45%Gross marginGross mgn
938%n/mn/mn/m284%154%140%127%160%228%261%SG&A / revenueSG&A/rev
n/mn/mn/m972%165%115%104%104%200%379%429%R&D / revenueR&D/rev
($43M)($62M)($59M)($86M)($63M)($78M)($79M)($82M)($172M)($270M)($314M)Operating incomeOp. inc.
n/mn/mn/mn/m−361.1%−179.3%−152.7%−141.0%−269.6%−519.8%−603.0%Operating marginOp. mgn
($45M)($63M)($60M)($86M)($156M)($7M)($71M)($81M)($194M)($266M)($301M)Net incomeNet inc.
Cash flow & returns
($34M)($50M)($49M)($78M)($54M)($66M)($60M)($70M)($135M)($205M)($238M)Operating cash flowOp. cash
$881K$2M$2M$3M$3M$2M$2M$3M$4M$4M$5MDepreciation & amortizationD&A
$4M$4M$982K($2M)$92M($76M)($8M)($10M)$22M$14M$4MWorking capital & otherWC & other
$2M$8M$2M$2M$841K$1M$4M$6M$1M$12M$17MCapexCapex
101.7%429.1%94.9%52.9%4.8%2.7%7.2%10.4%2.0%23.1%32.4%Capex / revenueCapex/rev
($35M)($52M)($51M)($80M)($54M)($67M)($62M)($73M)($136M)($209M)($244M)Owner earningsOwner earn.
n/mn/mn/mn/m−312.6%−153.4%−119.8%−125.3%−213.4%−402.7%−468.1%Owner earnings marginOE mgn
($36M)($59M)($51M)($80M)($54M)($67M)($63M)($76M)($136M)($217M)($255M)Free cash flowFCF
n/mn/mn/mn/m−312.6%−153.4%−123.0%−130.6%−213.4%−417.5%−490.1%Free cash flow marginFCF mgn
$37M$27M($2M)($2M)($841K)($1M)($4M)($6M)($1M)($12M)Investing cash flowInv. cash
$585K$32M$69M$75M$228M$3M$1M$170M$332M$562MFinancing cash flowFin. cash
$4M$8M$18M($4M)$174M($64M)($62M)$94M$196M$345MChange in cashΔ cash
-103%-1864%-708%ROICROIC
-86%-242%-167%-205%-7%-201%-89%-61%-41%-58%Return on equityROE
−86%−242%−167%−205%−7%−201%−89%−61%−41%−58%Retained to equityRetained/eq
Balance sheet
$33M$42M$54M$54M$228M$164M$102M$196M$392M$737M$599MCash & investmentsCash+inv
$250K$226K$201K$3M$12M$21M$21M$26M$32M$31M$30MReceivablesReceiv.
$113K$122K$217K$954K$1M$1M$2M$2M$3M$4M$4MInventoryInvent.
$2M$4M$3M$3M$3M$5M$5M$4M$4M$4M$7MAccounts payablePayables
($2M)($3M)($3M)$234K$11M$18M$18M$24M$31M$30M$27MOperating working capitalOper. WC
$70M$43M$56M$60M$246M$191M$130M$232M$441M$782M$644MCurrent assetsCur. assets
$8M$13M$9M$12M$27M$26M$31M$35M$41M$51M$49MCurrent liabilitiesCur. liab.
8.4×3.2×6.1×5.0×9.2×7.3×4.1×6.7×10.7×15.4×13.1×Current ratioCurr. ratio
$3M$10M$10M$10M$8M$7M$10M$12M$9M$20MNet PP&ENet PP&E
$75M$55M$73M$79M$262M$205M$149M$252M$458M$808M$671MTotal assetsAssets
$14M$18M$25M$25M$24M$26M$29M$66M$69M$71M$73MTotal debtDebt
($19M)($24M)($29M)($29M)($204M)($138M)($74M)($130M)($324M)($666M)($526M)Net debt / (cash)Net debt
-25.8×-32.7×-34.0×-14.1×-9.3×-11.7×-11.2×-7.3×-12.7×-22.8×-27.5×Interest coverageInt. cov.
$23M$29M$37M$82M$186M$117M$114M$161M$143M$154MTotal liabilitiesTotal liab.
$52M$26M$36M($4M)$76M$88M$35M$91M$315M$654M$520MShareholders’ equityEquity
315.6%380.7%376.0%207.2%43.3%34.4%32.9%30.5%52.0%83.1%102.4%Stock comp / revenueSBC/rev
Per share
24.8M28.8M38.1M45.3M60.8M82.2M82.6M85.6M158M187M225MShares out (diluted)Shares
$0.08$0.07$0.05$0.09$0.29$0.53$0.62$0.68$0.40$0.28$0.23Revenue / shareRev/sh
$-1.80$-2.20$-1.57$-1.91$-2.56$-0.08$-0.86$-0.94$-1.22$-1.42$-1.34EPS (diluted)EPS
$-1.41$-1.81$-1.34$-1.76$-0.90$-0.81$-0.75$-0.86$-0.86$-1.12$-1.09Owner earnings / shareOE/sh
$-1.45$-2.04$-1.34$-1.76$-0.90$-0.81$-0.77$-0.89$-0.86$-1.16$-1.14Free cash flow / shareFCF/sh
$0.08$0.29$0.05$0.05$0.01$0.01$0.04$0.07$0.01$0.06$0.08Cap. spending / shareCapex/sh
$2.10$0.91$0.94$-0.08$1.25$1.07$0.43$1.06$1.99$3.49$2.32Book value / shareBVPS

The diluted share count moved ×1.85 into 2024 — shares issued, not a split the totals corroborate — and the per-share figures carry the counts as filed.

Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+15.5%/yr−0.6%/yr
Capital spending / share−2.1%/yr+35.9%/yr
Book value / share+5.8%/yr+22.8%/yr

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2025 the business earned ($209M) of owner earnings, the operating cash left after the $4M it takes just to hold its position. It put $8M more into growth; free cash flow, after that spending, was ($217M).

FY2025FY2024FY2023FY2022FY2021
Reported net income($266M)($194M)($81M)($71M)($7M)
Depreciation & amortizationnon-cash charge added back+$4M+$4M+$3M+$2M+$2M
Stock-based compensationreal costnon-cash, but a real cost+$43M+$33M+$18M+$17M+$15M
Working capital & othertiming of cash in and out, other non-cash items+$14M+$22M−$10M−$8M−$76M
Cash from operations($205M)($135M)($70M)($60M)($66M)
Maintenance capital expenditurethe spending needed just to hold position and volume−$4M−$1M−$3M−$2M−$1M
Owner earnings($209M)($136M)($73M)($62M)($67M)
Growth capital expenditurediscretionary; spent to get bigger, not to stand still−$8M−$3M−$2M
Free cash flow($217M)($136M)($76M)($63M)($67M)
Owner-earnings marginowner earnings ÷ revenue-403%-213%-125%-120%-153%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the maintenance capital it must spend to hold its position (here about $4M, roughly its depreciation, the rate its assets wear out). The other $8M of its capital spending is growth it chose, not upkeep it owed; charged only with the maintenance it must do, the business earns well more than the year's free cash flow shows. The cash-flow statement also adds stock comp back as non-cash, but it is a real cost paid in shares; counted as the expense it is (less $43M), owner earnings is nearer ($252M).

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

III

Quality & stewardship

Returns, the balance sheet, capital allocation, and pay.

Owner’s Scorecard

FY2025 10-K · source on SEC EDGAR →

Will it survive?

  • Does not cover its interest
    Operating income ($270M) ÷ interest expense $12M
    What this means

    A full year of operating profit didn't cover the interest bill. This is the zombie zone: the business depends on refinancing, asset sales, or forbearance to service its debt.

  • Net cash
    Cash $737M − debt $71M
    What this means

    Cash and short-term investments exceed every dollar of debt by $666M, on net the company owes nothing, and can act from strength when others can't. Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 215 + DIO 198 − DPO 231 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Not meaningful here
    Invested capital ($11M) = debt $71M + equity $654M − cash
    Industry peers: median -46%
    What this means

    Invested capital is near zero or negative, usually years of buybacks pulling equity down. ROIC explodes or flips sign and stops meaning anything. Judge this one on Owner Earnings instead.

  • Consumes cash through the cycle
    6-yr median margin, range -403%–-120%; latest ($209M) = operating cash ($205M) − maintenance capex $4M
    Industry peers: median -212%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's -403% of revenue this year, a -183% median across 6 years. Treating stock comp as the real expense it is (less $43M of SBC) leaves ($252M).

  • Loss, and burning cash
    Net income ($266M) · cash from operations ($205M)
    What this means

    The company reported a net loss, so a conversion ratio isn't meaningful. What matters then is whether operations still threw off cash, here, they did not.

How is the cash used?

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

  • Investing or harvesting? 2.78×
    Expanding
    Capex $12M ÷ depreciation & amortization as filed $4M
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

The promise and the pay packet

  • Growth is being bought
    Selling and marketing $54M ÷ revenue $52M
    What this means

    Sales and marketing as a share of revenue, kept apart from administrative overhead because it answers a different question: how much a business must spend to win the next customer. A company whose product pulls customers in spends little here and keeps the difference; one that must buy its growth is running to stand still, and the spending has to keep rising for revenue to keep rising. Read it beside the growth rate, not alone.

  • Is the buyback buying ownership, or mopping up? 83.1%
    Stock pay, share count unread
    Stock compensation $43M (fiscal 2025), 83.1% of revenue · no repurchases · the share count is not comparable across these years (a split or a first listing sits in the record), so the drift is withheld
    What this means

    Stock handed to employees is a real cost paid in the owner's own currency: it is charged against profit, but the shares it creates are permanent. Many companies repurchase stock at the same time, which looks like a return of capital and often is not — if the count barely moves, the cash merely cancelled the pay packet and bought the owner nothing. The three states worth telling apart are a count genuinely shrinking, a count standing still despite large repurchases, and a count rising because the issuance was never offset at all.

Graham’s defensive tests · 2 of 4 met

Graham’s numerical criteria for the defensive investor (The Intelligent Investor, ch. 14), run on the filings. A floor of safety, not a buy signal; many fine modern businesses fail his strictest liquidity rules by design.

  • Adequate size Miss
    Revenue ≥ $2B · $52M
    What this means

    Big enough to weather a storm. Graham's 1972 floor was ~$100M of sales (≈ $700M today); we use a $2B revenue line as a conservative modern stand-in.

  • Strong liquidity Pass
    Current ratio ≥ 2× · 15.39×
    What this means

    Current assets at least twice current liabilities, near-term bills covered without touching the business. Strict by design: many cash-rich modern firms run leaner and miss it, holding their cushion in longer-dated securities.

  • Conservative debt Pass
    Debt ≤ working capital · $71M vs $731M WC
    What this means

    Graham's rule that borrowings not exceed net current assets. Capital-heavy and buyback-heavy firms routinely fail it, read it next to interest coverage, not alone.

  • Earnings stability Miss
    A profit every year (10-yr record) · 10 loss years
    What this means

    Graham wanted earnings in each of the past ten years, the stability a defensive owner leans on.

  • Dividend record
    Uninterrupted dividends · no dividend line tagged in the data
    What this means

    An unbroken dividend was Graham's mark of durability. This record carries no dividends-paid line in any year — common for partnerships, whose distributions file under tags the chain doesn't read — so the criterion is withheld rather than judged on silence.

  • Earnings growth
    Earnings +33% over the record ·
    What this means

    Earnings were negative early in the record, a growth rate isn't meaningful.

  • Moderate price
    P/E ≤ 15 and P/E × P/B ≤ 22.5 · decided by the price
    What this means

    Graham's valuation gate, the wall he kept between a sound business and a sound investment. Three-year average earnings are $-0.82/share (latest year $-1.21), the averaged base the calculator's gate runs on, and book value is $2.98/share. Enter a price in “What the price implies” just below for the P/E, P/B, and whether it clears. But this is the rule Buffett outgrew: there's no hard P/E law, and a wonderful business can deserve a far richer multiple if the thesis holds, treat it as the bargain-hunter's floor, not a verdict on the price.

Durability & moat, 2016–2025

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 0 of 10
    What this means

    Lost money in 10 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 0 of 3 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin −2829% → −310% (3-yr avg ends)

    In the filing’s words The filing ties gains to its own pricing, but names price competition too — pricing power that is real yet contested, not unopposed. The margin shows who is winning.

    What this means

    Through the cycle the operating margin widened — about −2829% early to −310% lately, median −520% — pricing power intact or improving.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Worst year 2017 · −3220.1% op. margin
    What this means

    Operations went underwater in 2017, understand why before trusting the good years.

All figures as filed; the source filing is linked above.

Current Position

as of the latest quarter, Jun 30, 2026

Can the business pay what it owes this year, off the freshest balance sheet: the quality of the assets, the debt actually coming due, and what a low ratio means here.

Current assets$644M
  • Cash & short-term investments$599M
  • Receivables$30M
  • Inventory$4M
  • Other current assets$12M
Current liabilities$49M
  • Accounts payable$7M
  • Other current liabilities$42M
Current ratio13.11×all current assets ÷ what's due · Graham looked for 2×
Quick ratio13.03×stricter: inventory excluded
Cash ratio12.17×strictest: cash alone against what's due
Working capital$595Mthe cushion left after near-term bills
Cash runway2.3 yrsthe business is consuming cash; this is how long the cash on hand lasts at that rate
Revenue, latest quarter vs. a year ago+0.1%the freshest read on whether the business is still growing
Current ratio, recent quarters13.0× → 13.1×
Deeper floors
Tangible book value$520Mequity stripped of goodwill & intangibles
Net current asset value$493MGraham's net-net: current assets less all liabilities
Debt incl. operating leases$7M$7M of it operating leases
Deferred revenue$14Mcustomer cash collected before delivery; operating float

From the company's latest filing.

Management, ownership & pay

read the proxy →

From the proxy: how much of the business the people running it own, and how they are paid, beside what the business earned for its owners in the same years.

Fiscal yearChief executivePay, as filed“Actually paid”Owner earnings
2021Dr. Dugel$7.1M−$4.2M($67M)
2022Dr. Dugel$4.1M−$2.1M($62M)
2023Dr. Dugel$3.3M$1.0M($73M)
2024Dr. Dugel$8.8M$5.8M($136M)
2024Dr. Dugel$18.6M$9.6M($136M)
2025Dr. Dugel$35.9M$57.5M($209M)

Both pay figures are the company’s own, from the pay-versus-performance table its proxy statement files. “As filed” is the Summary Compensation Table total: salary, bonus, and equity awards at their value on the day of grant. “Actually paid” is the SEC’s prescribed recalculation, which re-marks those equity awards to what they became as they vested; it can swing far above or below the filed figure in either direction, and negative years occur. Owner earnings are the whole business's, from the record above, for the same fiscal years.

  • Insider ownership3.1%

    The stake all directors and executive officers hold together, per the 2026 proxy: skin in the game, the first thing Munger reads.

  • CEO pay ratio145:1

    What the chief earns for every dollar the median employee makes, per the 2026 proxy. A high ratio alone settles nothing; some businesses are genuinely top-heavy in scarce skill. A runaway figure is where Buffett starts asking whether the board is doing its job.

  • Stock-based compensation$43M

    The slice of the business handed to employees in shares in fiscal 2025, 83.1% of revenue. Buffett's oldest accounting fight: this is compensation, compensation is an expense, real whether or not the headline earnings admit it. One trap: the cash-flow statement adds SBC back, so the operating cash, and the owner earnings drawn from it, are flattered by exactly this amount; counted as the cost it is, what an owner keeps is lower.

What an owner would ask, FY2025

read the 10-K →
  • Which reported numbers are a judgment call?
    Management names Revenue recognition, Stock compensation as critical estimates

    each rests partly on management's judgment; the filing's note sets out the assumptionsverify →

The questions the record and the charts do not answer on their own; each carries the figure and the place to look.

Peers, Pharmaceuticals

The same industry, side by side on owner economics. Each column names the period it is read over, and a median resting on fewer than three years carries that count beside it; the group median at the foot is the line to read each figure against.

CompanyRevenuelatest FY, USDGross marginmedian over the recordOp. marginmedian over the recordROICmedian over the recordOwner earn. marginmedian over the record
ENTAEnanta Pharmaceuticals Inc.$65M-73.4%-17%-22%
NUVBNuvation Bio Inc.$63M10%1y-338.7%1y-89%-278%1y
NKTRNektar Therapeutics$55M81%-265.8%-46%-212%
AGIOAgios Pharmaceuticals Inc.$54M89%-384.0%-44%-330%
XOMAXOMA Royalty Corporation$52M-21.1%-16%-131%
OCULOcular Therapeutix Inc.$52M76%4y-224.4%-708%3y-183%
LXRXLexicon Pharmaceuticals Inc.$50M98%-160.5%-63%-222%
PTGXProtagonist Therapeutics Inc.$46M-207.1%-56%-141%
Group median81%-215.8%-51%-198%
IV

The price

What a price has to assume.

What the price implies

reverse-DCF

Ocular Therapeutix Inc. is profitable, but owner earnings are negative this year because capital spending currently outruns operating cash, a build-out, so the owner-earnings reverse-DCF has no positive base to grow. We read the price from both ends instead: type a price to see the steady-state profitability it demands, then set the mature margin you would believe and weigh the two against each other. Nothing leaves your browser unless you enter it in your notebook.

$
The assumptions

Revenue, delivered21%/yr’20→’25

Enter a price to run it.

Owner earnings it must reach
Margin the price demands
Owner-earnings margin today−490%

Two reads of one future. From your price: the owner earnings the company must reach, valued at a mature multiple and discounted back at your rate, expressed as the margin it implies on revenue grown at your rate. From your belief: the mature margin you would credit, set on the dial above. When the margin the price demands runs above the one you would believe, you are paying for a future taken on faith. For a deep cyclical at a trough, normalized through-cycle earnings are the better lens; this mode is for the genuinely unprofitable, and for the profitable business whose capital spending currently outruns its cash.

Cite: Owner Scorecard, "Ocular Therapeutix Inc. (OCUL), the owner's record," https://ownerscorecard.com/c/OCUL, data as of 2026-08-17.

Manual order: ← OCGN its page in the Manual ODC →

Industry order: ← NVS the Pharmaceuticals chapter OGI →